Aims: To compare the antianginal efficacy of trimetazidine with that of other agents with no influence on heart rate. Methods and Results: Medline and Embase databases were searched for blinded, randomized, controlled trials assessing the effects of non-heart-rate-lowering antianginal treatments on exercise tolerance and/or clinical criteria in stable angina patients. All relevant trimetazidine trials including the VASCO trial, the results of which are published herein, were included. A Bayesian network meta-analysis on the summary data was performed. Comparator antianginal agents were considered as a group and in agent/class subgroups. Trials involving β-blockers, non-dihydropyridine calcium channel blockers, and ivabradine were excluded. 218 trials totaling 19,028 patients were included in at least 1 network analysis. Effects of trimetazidine were statistically significant compared with placebo for exercise tolerance and clinical criteria. Transposition of results into seconds for clinical interpretation of exercise tolerance parameters showed a mean improvement of +46 s (95% credibility interval: 28; 66) for total exercise duration, +55 s (35; 77) for 1-mm ST segment depression (T1), and +54 s (24; 84) for time to onset of angina, in favor of trimetazidine. Differences between trimetazidine and active comparators were not significant when exercise tolerance and clinical criteria were analyzed, with +7 s (–12; 28) for total exercise duration, –1 s (–23; 22) for T1, +8 s (–22; 40) for time to onset of angina, and –0.28 (–1.17; 0.64) attacks per week for trimetazidine compared with antianginal agents as a group. Conclusions: Trimetazidine efficacy was comparable to that of other non-heart-rate-lowering antianginal treatments in patients with stable angina pectoris.

Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F,et al: Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006;27:1341–1381.
Dalla-Volta S, Maraglino G, Della-Valentina P, Viena P, Desideri A: Comparison of trimetazidine with nifedipine in effort angina: a double-blind, crossover study. Cardiovasc Drugs Ther 1990;4(suppl 4):853–859.
Szwed H, Sadowski Z, Elikowski W, Koronkiewicz A, Mamcarz A, Orszulak W, et al: Combination treatment in stable effort angina using trimetazidine and metoprolol: results of a randomized, double-blind, multicentre study (TRIMPOL II). TRIMetazidine in POLand. Eur Heart J 2001;22:2267–2274.
Kantor PF, Lucien A, Kozak R, Lopaschuk GD: The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:580–588.
Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS, Stanley WC: Myocardial fatty acid metabolism in health and disease. Physiol Rev 2010;90:207–258.
Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G, et al: Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006;27:942–948.
Marzilli M, Klein WW: Efficacy and tolerability of trimetazidine in stable angina: a meta-analysis of randomized, double-blind, controlled trials. Coron Artery Dis 2003;14:171–179.
Cesar LA, Gowdak LH, Mansur AP: The metabolic treatment of patients with coronary artery disease: effects on quality of life and effort angina. Curr Pharm Des 2009;15:841–849.
Ciapponi A, Pizarro R, Harrison J: Trimetazidine for stable angina. Cochrane Database Syst Rev 2005:CD003614.
Sellier P, Broustet JP: Assessment of anti-ischemic and antianginal effect at trough plasma concentration and safety of trimetazidine MR 35 mg in patients with stable angina pectoris: a multicenter, double-blind, placebo-controlled study. Am J Cardiovasc Drugs 2003;3:361–369.
El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S: Effects of trimetazidine on myocardial perfusion and the contractile response of chronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 2005;5:271–278.
Gao D, Ning N, Niu X, Hao G, Meng Z: Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart 2011;97:278–286.
Lu G, Ades AE: Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;23:3105–3124.
Jansen JP, Crawford B, Bergman G, Stam W: Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008;11:956–964.
Dias S, Welton NJ, Caldwell DM, Ades AE: Checking consistency in mixed treatment comparison meta-analysis. Stat Med 2010;29:932–944.
Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560.
Michaelides A, Spiropoulos K, Dimopoulos K, Athanasiades D, Tontouzas P: Antianginal efficacy of the combination of trimetazidine-propranolol compared with isosorbide dinitrate propranolol in patients with stable angina. Clin Drug Investig 1997;13:8–14.
Hanania G, Haiat R, Olive T, Maalouf B, Michel D, Martelet M, et al: Coronary artery disease observed in general hospitals: ETTIC study. Comparison between trimetazidine and mononitrate isosorbide for patients receiving betablockers (in French). Ann Cardiol Angeiol (Paris) 2002;51:268–274.
Jackson G: Stable angina: maximal medical therapy is not the same as optimal medical therapy. Int J Clin Pract 2000;54:351.
Makolkin VI, Osadchiy KK: Trimetazidine Modified Release in the Treatment of Stable Angina: TRIUMPH StudyTRImetazidine MR in Patients with Stable Angina: Unique Metabolic PatH. Clin Drug Investig 2004;24:731–738.
Lu C, Dabrowski P, Fragasso G, Chierchia SL: Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998;82:898–901.
Shlyakhto EV, Almazov VV, Nifontov EM, Vakhrameyeva IV, Rudomanov OG, Zakharov DV, et al: Antianginal effects of trimetazidine and left ventricular function improvement in patients with stable angina pectoris. Am J Cardiovasc Drugs 2002;2:119–124.
Di Napoli P, Di Giovanni P, Gaeta MA, Taccardi AA, Barsotti A: Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d’Abruzzo Trimetazidine Trial. J Cardiovasc Pharmacol 2007;50:585–589.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.